Análisis comparativo de las medidas de prevención nacionales e internacionales para cirrosis hepática alcohólica
Palabras clave:
Cirrosis hepática alcohólica, Prevención primaria, Prevención secundaria, Prevención terciariaResumen
Introducción: La cirrosis hepática alcohólica (CHa) es una enfermedad invalidante que, dado el aumento de consumo de alcohol en Chile, podría aumentar su incidencia en los próximos años, haciendo relevante la búsqueda y mejoría de estrategias para abordar esta patología. Objetivos: Comparar, mediante una revisión bibliográfica, medidas nacionales e internacionales de prevención de CHa primaria, secundaria y terciaria respecto a la cirrosis hepática alcohólica. Metodología: Se utilizaron términos clave MeSH y libres para la búsqueda de artículos en literatura gris e indexada, más criterios de inclusión. Se obtuvieron 402 trabajos de literatura indexada, de los cuales se seleccionaron 41, en adición a 12 de literatura gris. Discusión: Del análisis de textos se desprende que Chile posee medidas de prevención primaria similares a las recomendadas internacionalmente, a diferencia de la prevención secundaria y terciaria, que se aborda de forma incompleta u omite aspectos del manejo de CHa y sus complicaciones. Conclusiones: En Chile existe un déficit frente al mundo en las medidas de prevención secundaria y terciaria de CHa. En consecuencia, se recomienda evaluar la aplicabilidad de tales medidas para incorporarlas al plan de manejo nacional de CHa.
Descargas
Citas
Patel R, Mueller M. Alcoholic Liver Disease. 2022 Jan 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31536239.
Zhou W, Zhang Q, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014;20:7312. https://doi.org/10.3748/WJG.V20.I23.7312.
Axley PD, Richardson CT, Singal AK. Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease. Clin Liver Dis. 2019 Feb;23(1):39-50. doi: 10.1016/j.cld.2018.09.011. PMID: 30454831.
Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., ... & Padubidri, J. R. (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet gastroenterology & hepatology, 5(3), 245-266.
Cuba L, Lazarte R, Pavez C, Poniachik J. Artículo de Revisión 18 Enfermedad hepática por alcohol 2016;27:18–30.
Ministerio de Salud de Chile, SENDA. El consumo de alcohol en Chile: Situación epidemiológica [internet]. 2016 [consultado 26 Nov 2021]. Disponible en: https://www.senda.gob.cl/wp-content/uploads/media/estudios/otrosSENDA/2016_Consumo_Alcohol_Chile.pdf
Alonso Faustino Tomás, Garmendia María Luisa, De Aguirre Magdalena, Serale Javier. Análisis de la tendencia de la mortalidad por cirrosis hepática en Chile: Años 1990 a 2007. Rev. méd. Chile [Internet]. 2010 Oct [citado 2021 Nov 27] ; 138( 10 ): 1253-1258.
Ministerio de Salud de Chile, SENDA. El consumo de alcohol en Chile: Situación epidemiológica [internet]. 2016 [consultado 26 Nov 2021]. Disponible en: https://www.senda.gob.cl/wp-content/uploads/media/estudios/otrosSENDA/2016_Consumo_Alcohol_Chile.pdf
Askgaard G, Kjær MS, Tolstrup JS. Opportunities to prevent alcoholic liver cirrhosis in high-risk populations: a systematic review with meta-analysis. Official journal of the American College of Gastroenterology| ACG. 2019 Feb 1;114(2):221-32.
Patton R, Deluca P, Kaner E, Newbzury-Birch D, Phillips T, Drummond C. Alcohol screening and brief intervention for adolescents: the how, what and where of reducing alcohol consumption and related harm among young people. Alcohol and alcoholism. 2014 Mar 1;49(2):207-12.
Colbert S, Wilkinson C, Thornton L, Feng X, Richmond R. Online alcohol sales and home delivery: An international policy review and systematic literature review. Health policy. 2021 Jul 18
Korczak D, Steinhauser G, Dietl M. Prevention of alcohol misuse among children, youths and young adults. GMS health technology assessment. 2011;7.
Baccini M, Carreras G. Analyzing and comparing the association between control policy measures and alcohol consumption in Europe. Substance Use & Misuse. 2014 Oct 15;49(12):1684-91.
Stockings E, Hall WD, Lynskey M, Morley KI, Reavley N, Strang J, Patton G, Degenhardt L. Prevention, early intervention, harm reduction, and treatment of substance use in young people. The Lancet Psychiatry. 2016 Mar 1;3(3):280-96.
Villalbí JR, Bosque-Prous M, Gili-Miner M, Espelt A, Brugal MT. Políticas para prevenir los daños causados por el alcohol. Rev Esp Salud Publica. 2014;88(4):515–28.
Pavlov CS, Casazza G, Nikolova D, Ivashkin VT, Gluud C. Transient elastography for diagnosis of hepatic fibrosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2013;2013(5).
Nguyen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(9):614–25.
National Institute for Health and Care Excellence. FibroScan for assessing liver fibrosis and cirrhosis in primary care[Internet]. [London]: NICE; 2020. (Advice [MIB216]). Available from: https://www.nice.org.uk/advice/mib216
Marín-Serrano Eva, Segura-Cabral José María. Utilidad de la ultrasonografía en el diagnóstico de las enfermedades hepáticas difusas. Rev. esp. enferm. dig. [Internet]. 2011 Mayo [citado 2021 Nov 25] ; 103( 5 ): 227-231. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082011000500001&lng=es. https://dx.doi.org/10.4321/S1130-01082011000500001.
Pavlov CS, Casazza G, Pavlova M, Nikolova D, Tsochatzis E, Liusina E, et al. Ultrasonography for diagnosis of cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015;2015(3).
Haghgoo SM, Sharafi H, Alavian SM. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: A systematic review. Clin Chem Lab Med. 2019;57(5):577–610.
National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management [Internet]. [London]: NICE; 2016. (Clinical guideline [NG50]). Available from: https://www.nice.org.uk/guidance/ng50
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020). Diagnosis and treatment of alcohol‐associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 71(1), 306-333.
Vuittonet CL, Halse M, Leggio L, Fricchione SB, Brickley M, Haass-Koffler CL, Tavares T, Swift RM, Kenna GA. Pharmacotherapy for alcoholic patients with alcoholic liver disease. American journal of health-system pharmacy. 2014 Aug 1;71(15):1265-76.
Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane database of systematic reviews. 2012.
Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521-1530.e8.
Wan S, Huang C, Zhu X. Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients. BMJ Open. 2019;9(7):e030038.
Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60(2):255–60.
Vuittonet CL, Halse M, Leggio L, Fricchione SB, Brickley M, Haass-Koffler CL, et al. Pharmacotherapy for alcoholic patients with alcoholic liver disease. Am J Health Syst Pharm. 2014;71(15):1265–76.
Benmassaoud A, Freeman SC, Roccarina D, Plaz Torres MC, Sutton AJ, Cooper NJ, et al. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:CD013123.
Ros Ruiz S, Gutiérrez Vilchez E, García Frías TP, Velázquez M, Blanca Martos L, Jiménez Salcedo T, et al. Papel de la diálisis peritoneal en el tratamiento de la ascitis. Nefrología (Madrid. 2011;31(6):648–655.
Prat LI, Wilson P, Freeman SC, Sutton AJ, Cooper NJ, Roccarina D, et al. Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta‐analysis. Cochrane Database of Systematic Reviews. 2019;9.
Butterworth RF. Hepatic encephalopathy in alcoholic cirrhosis. In: Handbook of Clinical Neurology. Elsevier; 2014. p. 589–602.
Kamal F, Khan MA, Khan Z, Cholankeril G, Hammad TA, Lee WM, Ahmed A, Waters B, Howden CW, Nair S, Satapathy SK. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. European journal of gastroenterology & hepatology. 2017 Oct 1;29(10):1109-17.
Best LM, Freeman SC, Sutton AJ, Cooper NJ, Tng EL, Csenar M, Hawkins N, Pavlov CS, Davidson BR, Thorburn D, Cowlin M. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta‐analysis. Cochrane Database of Systematic Reviews. 2019(9).
Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. Medicine. 2018 Apr;97(16).
Song T, Rössle M, He F, Liu F, Guo X, Qi X. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Digestive and Liver Disease. 2018 Apr 1;50(4):323-3
Kerbert AJ, Chiang FW, van der Werf M, Stijnen T, Slingerland H, Verspaget HW, van Hoek B, Coenraad MJ. Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. European journal of gastroenterology & hepatology. 2017 Apr 1;29(4):380-7.
Vadera S, Yong CW, Gluud LL, Morgan MY. Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and esophageal varices. Cochrane Database of Systematic Reviews. 2019 (6)
Mohan BP, Chandan S, Khan SR, Kassab LL, Trakroo S, Ponnada S, Asokkumar R, Adler DG. Efficacy and safety of endoscopic ultrasound-guided therapy versus direct endoscopic glue injection therapy for gastric varices: systematic review and meta-analysis. Endoscopy. 2020 Apr;52(04):259-67.
Saad WE, Darcy MD. Transjugular intrahepatic portosystemic shunt (TIPS) versus balloon-occluded retrograde transvenous obliteration (BRTO) for the management of gastric varices. InSeminars in interventional radiology 2011 Sep (Vol. 28, No. 03, pp. 339-349). © Thieme Medical Publishers
Yu H, Guo S, Wang L, Dong Y, Tian G, Mu S, Zhang H, Li D, Zhao S. Laparoscopic splenectomy and esophagogastric devascularization for liver cirrhosis and portal hypertension is a safe, effective, and minimally invasive operation. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2016 Jul 1;26(7):524-30.
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS medicine. 2014 Apr 1;11(4):e1001624.
McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—A meta-analysis. European Journal of Cancer. 2018 Dec 1;105:1-9.
Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, Mallat A, Launoy G, Laurent A. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: an attempt to perform an ideal meta‐analysis. Liver Transplantation. 2017 Jun;23(6):836-44.
Singal AK, Freeman Jr DH, Anand BS. Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Alimentary pharmacology & therapeutics. 2010 Oct;32(7):851-8.
Marot A, Dubois M, Trépo E, Moreno C, Deltenre P. Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. PLoS One. 2018;13(1):e0190823.
Donoso MP. Análisis de Resultados del Alcohol Use Disorders Identification Test (AUDIT) Resultados Escala. Boletín N°3. 2015 [15 de noviembre de 2021]; p.1-6. Disponible en: https://www.senda.gob.cl/wp-content/uploads/boletines/Boletin%203%20An%C3%A1lisis%20de%20Resultados%20del%20Alcohol%20Use%20Disorders%20Identification%20Test%20(AUDIT)%20Resultados%20Escala.pdf
Ministerio de Salud de Chile. Intervenciones breves para reducir el consumo de alcohol de riesgo: Guía técnica para atención primaria en salud [Internet]. 2011 [Consultado 26 Nov 2021]. Disponible en: https://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2016/02/5.-MINSAL_2011_-Intervenciones-breves-alcohol.pdf
Ministerio de Salud de Chile. Intervenciones breves para reducir el consumo de alcohol de riesgo: Guía técnica para atención primaria en salud [Internet]. 2011 [Consultado 26 Nov 2021]. Disponible en: https://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2016/02/5.-MINSAL_2011_-Intervenciones-breves-alcohol.pdf
Ministerio de Salud de Chile. Estrategia Nacional sobre Alcohol: reducción del consumo de riesgo y sus consecuencias sociales y sanitarias [Internet]. 2010. [Consultado 26 Nov 2021]. Disponible en: https://www.minsal.cl/sites/default/files/files/2%20Estrategia%20Nacional%20sobre%20Alcohol_b.pdf
Biblioteca del Congreso Nacional. Ley 21.363: Establece normas en materia de comercialización y publicidad de bebidas alcohólicas [Internet]. Chile; 2021. [Consultado el 26 Nov 2021]. Disponible en: https://www.bcn.cl/leychile/navegar?idNorma=1163383
Weitz JC. Diagnóstico y tratamiento de las enfermedades digestivas. Santiago de Chile: Sociedad Chilena de Gastroenterología; 2013. [Consultado el 26 Nov]. Disponible en: http://www.sociedadgastro.cl/gastroweb/index.php/publicaciones/e-books/manual-2013
